ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BVXP Bioventix Plc

4,150.00
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix Plc LSE:BVXP London Ordinary Share GB00B4QVDF07 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 4,150.00 66 01:00:00
Bid Price Offer Price High Price Low Price Open Price
4,100.00 4,200.00 4,150.00 4,150.00 4,150.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 12.82M 8.37M 1.6071 25.82 216.19M
Last Trade Time Trade Type Trade Size Trade Price Currency
10:33:59 O 34 4,101.00 GBX

Bioventix (BVXP) Latest News

Bioventix (BVXP) Discussions and Chat

Bioventix Forums and Chat

Date Time Title Posts
07/6/202410:00Bioventix - Sheep Antibodies1,578
08/11/201613:07ShareSoc Supper in Brighton-

Add a New Thread

Bioventix (BVXP) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
09:34:014,101.00341,394.34O
07:55:324,101.00301,230.30O
07:30:054,118.00282.36O
2024-07-15 15:37:394,120.001,05043,260.00O
2024-07-15 15:06:314,101.007287.07O

Bioventix (BVXP) Top Chat Posts

Top Posts
Posted at 16/7/2024 09:20 by Bioventix Daily Update
Bioventix Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker BVXP. The last closing price for Bioventix was 4,150p.
Bioventix currently has 5,209,333 shares in issue. The market capitalisation of Bioventix is £216,187,320.
Bioventix has a price to earnings ratio (PE ratio) of 25.82.
This morning BVXP shares opened at 4,150p
Posted at 23/5/2024 09:39 by gsbmba99
“Building on the foundation our team developed last year, Quanterix is entering a new innovation and product delivery phase,” said Masoud Toloue, Chief Executive Officer of Quanterix. “We’ve announced the first of several new assays that could re-define the way Tau is measured from the brain versus peripheral sources. We will continue to lead in bringing novel biomarker detection solutions to market for the research community; developing tests to study and enable the early detection of neuro-pathologies such as Multiple Sclerosis, Parkinson’s, and Alzheimer’s disease.” ( A bit unclear but maybe brain-derived tau?

Page 6 of the accompanying results presentation makes it clear Mr. Toloue is indeed talking about Quanterix introducing an assay for brain-derived tau in Q2 ( Could this be a first commercial success for the UGOT/BVXP BD-tau antibody?
Posted at 25/3/2024 10:39 by melody9999
I see Cavendish have raised their price target to 5900p from 4400p in Oct 23. Will be happy to see the BVXP once again climb above the Cavendish target price!
Posted at 21/2/2024 10:34 by stepone68
Share price starting with a '5' now. Certainly feels like it is popular at the moment.
Posted at 12/2/2024 12:37 by maddox
BVXP are in the running to develop what has been described as the 'Holy Grail' of diagnostic testing - an early stage Alzheimer's test.

BBC Radio 4 Today report on new Alzheimer's treatments. Mentions that there are about 28 dementia drugs in late stage development. Whilst the current two leading drugs show efficacy the promise is of better drugs being developed.

The need for an early stage diagnostic test is clear in this report. Arguably, it's equally as important to have a simple early stage test as the drugs.
Posted at 12/2/2024 12:16 by maddox
A Director's sale, if well handled, can work to enhance the share price - you sell sufficient shares to entice in a new Financial Investor - but not sell them as big a holding as they which to have. They then need to buy in the open market, creating demand and supporting the share price whilst they accumulate their desired holding.

Can't say whether this is the case here but looks likely.
Posted at 24/1/2024 09:15 by alter ego
well researched 1c3479z. You're correct. I had conformation from Peter Harrison this morning. It does however, show the potential of the work being done by BVXP in this field.
Posted at 23/1/2024 16:42 by 1c3479z
not convinced- the journal article refers to an ALZpath validated immunoassay, did ALZpath also provide the antibody?
in any case, should this be validated, one expects the BVXP pTau 217 might have advantages over mouse monoclonals and be commercially in high demand from various diagnostics companies eg Roche etc with a long life cycle.
Posted at 23/1/2024 10:08 by alter ego
Can't be certain but it sounds like a BVXP SMA.

Sky news report today mentions " Measuring levels of a protein called p-tau217 in the blood...." "The study from Dr Nicholas Ashton at the University of Gothenburg, and colleagues, is published in the Jama Neurology journal."


From BVXP Annual Report for year ended 30/6/23

"A leading blood biomarker for “A” is a phosphorylated form of tau called pTau217. A prototype assay from Gothenburg using an SMA has now been established which has performed well with frozen patient samples from a number of different cohorts." and
"A novel blood-based prototype assay for neurodegeneration (N) using another Tau SMA has also been developed in Gothenburg. This work clearly supports the potential utility of this blood test and further work is ongoing in Gothenburg with further publications planned."
Posted at 30/10/2023 18:10 by maddox
I remember seeing an RNS from Norges Bank that had leant a tranch of shares. This explained the dip in the firm's share price - only to see the share price rebound strongly.... followed by another RNS from Norges Bank that had increased their holding. Presumably, they had picked up the shorters shares at a lower price and been paid for the privilege.
Posted at 30/10/2023 11:38 by stepone68
Very disappointing Troponin growth. 31%, vs. 81% last year. No divi increase either, which is a first. Alzheimers might hold the key, but we rely on these 12 people being smarter than the Chinese. Share price stagnant for the last 5 years.
Bioventix share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock